+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID04329494

Evaluating Safety and Effects of Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Advanced Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancers with Peritoneal Spread

Led by City of Hope Medical Center · Updated on 2026-08-26

49

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying pressurized intraperitoneal aerosol chemotherapy PIPAC to evaluate its safety and effects in patients with peritoneal carcinomatosis caused by ovarian, uterine, appendiceal, colorectal, or gastric cancers. This phase I trial aims to identify the maximum tolerated dose of PIPAC and assess safety across different patient groups, including those with advanced cancer spread to the abdominal lining. The study also explores response rates, surgical outcomes, progression-free survival, and patient quality of life. Participants are assigned to one of several groups based on their cancer type and prior treatments. Treatments involve PIPAC delivering chemotherapy drugs such as doxorubicin, cisplatin, oxaliplatin, mitomycin, and others directly into the abdomen through a minimally invasive laparoscopic procedure. Some groups receive additional intravenous chemotherapy drugs like leucovorin, fluorouracil, and irinotecan. Treatment cycles repeat every 4 to 6 weeks for up to three cycles if no disease progression or unacceptable side effects occur. During the study, participants undergo biopsies and imaging scans to evaluate tumor response using criteria like RECIST and peritoneal regression scores. Researchers also track surgical complications, technical success of PIPAC, and functional status through step monitoring devices. Quality-of-life questionnaires and symptom inventories are completed at regular intervals. After treatment, patients are followed every 12 weeks for up to three years to monitor outcomes and safety.

CONDITIONS

Brief Title

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here